Tarsus Pharmaceuticals, Inc. ( TARS ) NASDAQ Global Select

Cena: 57.16 ( 1.07% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Tarsus Pharmaceuticals, Inc., firma biofarmaceutyczna na stadium klinicznym, koncentruje się na rozwoju i komercjalizacji nowych kandydatów terapeutycznych na warunki okulistyczne. Jego głównym kandydatem na produkt jest TP-03, nowy terapeutyczny, który jest w fazie III w leczeniu zapalenia powiek spowodowanego infestacją roztoczy Demodex, a także do leczenia choroby gruczołu meibomicznego. Firma opracowuje również TP-04 w leczeniu trądziku różowatego; oraz TP-05 dla profilaktyki boreliozy i redukcji malarii społeczności. Ponadto firma opracowuje Lotilaner w celu rozwiązania problemów z chorobami w kategoriach terapeutycznych w medycynie ludzkiej, w tym o okulce, dermatologii i innych chorobach. Tarsus Pharmaceuticals, Inc. został zarejestrowany w 2016 roku i ma siedzibę w Irvine w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 244
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 74.4834
Ilość akcji: Brak danych
Debiut giełdowy: 2020-10-16
WWW: https://www.tarsusrx.com
CEO: Dr. Bobak R. Azamian M.D.
Adres: 15440 Laguna Canyon Road
Siedziba: 92618 Irvine
ISIN: US87650L1035
Wskaźniki finansowe
Kapitalizacja (USD) 2 413 169 027
Aktywa: 376 300 000
Cena: 57.16
Wskaźnik Altman Z-Score: 7.5
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -25.0
Ilość akcji w obrocie: 74%
Średni wolumen: 707 067
Ilość akcji 42 214 100
Wskaźniki finansowe
Przychody TTM 129 621 000
Zobowiązania: 138 816 000
Przedział 52 tyg.: 25.19 - 57.6
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -2.3
P/E branży: 28.3
Beta: 1.004
Raport okresowy: 2025-11-05
WWW: https://www.tarsusrx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 759 200 1968
Mr. Jeffrey S. Farrow Chief Financial Officer & Chief Strategy Officer 722 948 1962
Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary 619 087 1978
Dr. Elizabeth Yeu Lin M.D. Chief Medical Advisor & Director 59 125 1978
Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer 578 900 1977
Dr. Bobak R. Azamian M.D. Co-Founder, President, Chief Executive Officer & Chairman 1 083 000 0
Mr. David Nakasone Head of Investor Relations 0 0
Ms. Adrienne Kemp Senior Director of Corporate Communications 0 0
Mr. Matthew Rossen M.B.A. Vice President of Marketing 0 1978
Mr. Scott Youmans Vice President of Sales 0 0
Lista ETF z ekspozycją na akcje Tarsus Pharmaceuticals, Inc.
Symbol ETF Ilość akcji Wartość
IWM 958 561 37 211 320
IWO 350 933 13 623 200
IBB 228 374 8 865 480
VTWO 197 575 8 003 763
SCHA 181 028 7 165 912
PJP 148 316 5 932 640
XPH 135 747 5 463 919
IHE 106 425 4 131 400
VHT 104 040 4 214 660
ZPRR.DE 61 888 2 167 812
R2SC.L 61 888 1 875 924
R2US.L 61 888 2 475 520
USVM 59 442 2 307 538
ITOT 51 645 2 004 840
D5BM.DE 46 568 1 583 055
XSXD.L 46 568 1 807 760
XS5G.L 46 568 1 369 902
XS5E.DE 46 568 1 583 055
XSPU.L 46 568 1 807 760
XSPX.L 46 568 136 990 245
SMLF 37 333 1 449 280
DFAS 35 155 1 364 717
VTWG 34 280 1 388 682
NUSC 32 803 1 493 848
XMWD.L 32 308 1 254 200
DBXW.DE 32 308 1 098 302
XWEH.DE 32 308 1 098 302
FYC 28 716 1 215 835
2B70.DE 25 461 864 652
BTEC.L 25 461 988 400
BTEK.L 25 461 748 100
BTEE.L 25 461 988 400
XRS2.DE 23 998 815 802
XRSU.L 23 998 931 600
XRSG.L 23 998 70 595 716
SCHB 23 482 935 742
VFMO 22 522 912 366
IUSN.DE 22 016 747 674
WLDS.L 22 016 646 890
WSML.L 22 016 854 680
SBIO 20 110 780 670
ESML 20 067 802 680
RSSL 19 790 768 247
FHLC 14 108 589 009
ONEQ 13 356 557 613
FESM 13 316 555 943
FYX 12 664 536 193
BBP 10 852 453 071
BBSC 10 304 400 001
IWV 9 921 385 120
GSSC 9 781 403 857
CUS1.L 9 177 269 630
CUSS.L 9 177 356 240
SXRG.DE 9 177 311 638
CSUSS.MI 9 177 311 638
ISCG 8 090 314 040
XSU.TO 6 690 369 580
PILL 4 972 193 013
PRFZ 4 889 195 560
UWM 3 923 152 290
FAD 3 706 156 912
URTY 3 248 126 087
VTHR 2 956 119 747
VMO.TO 1 580 87 335
BIB 1 548 60 093
IBBQ 1 500 60 000
ISCB 1 358 52 720
MMSC 1 094 46 319
XUU.TO 910 50 246
USSC.L 392 13 658
ZPRV.DE 392 11 960
OMFS 389 15 560
XBAL.TO 290 16 003
EWSA.AS 183 7 120
CBUG.DE 183 6 228
XUH.TO 134 5 370
HDG 47 1 824
DCOR 8 310
XTR.TO 5 217
SBIO.L 0 478 074
SBIO.MI 0 418 889
RTYS.L 0 142 901
USUE.DE 0 0
SC0K.DE 0 125 209
USFM.L 0 0
PZW.TO 0 921
Wiadomości dla Tarsus Pharmaceuticals, Inc.
Tytuł Treść Źródło Aktualizacja Link
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2025-05-14 14:45:48 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demodex blepharitis, with trials set to initiate in H2'25 in ocular rosacea and 2026 for Lyme disease prevention. TARS is guiding for up to a 25% increase in bottles of Xdemvy dispensed in Q2'25, compared to Q1'25, although the company has often beaten its guidance for bottles dispensed. seekingalpha.com 2025-05-12 16:28:56 Czytaj oryginał (ang.)
Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: globenewswire.com 2025-05-08 21:00:00 Czytaj oryginał (ang.)
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. prnewswire.com 2025-05-05 10:27:00 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Officer and Chairman Aziz Mottiwala – Chief Commercial Officer Jeff Farrow – Chief Financial Officer and Chief Strategy Officer Sesha Neervannan – Chief Operating Officer Conference Call Participants Lachlan Hanbury-Brown – William Blair Andrea Newkirk – Goldman Sachs Pavan Patel – Bank of America Eddie Hickman – Guggenheim Cory Jubinville – LifeSci Capital Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to Tarsus First Quarter 2025 Earnings Conference Call. seekingalpha.com 2025-05-02 01:37:17 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago. zacks.com 2025-05-01 22:40:41 Czytaj oryginał (ang.)
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements Generated $78.3 million in net product sales of XDEMVY ® , an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients globenewswire.com 2025-05-01 20:05:00 Czytaj oryginał (ang.)
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com 2025-04-30 14:55:36 Czytaj oryginał (ang.)
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. globenewswire.com 2025-04-24 21:00:00 Czytaj oryginał (ang.)
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif. globenewswire.com 2025-04-22 12:31:00 Czytaj oryginał (ang.)
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com 2025-03-12 23:49:00 Czytaj oryginał (ang.)
Tarsus Announces Proposed $100.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. globenewswire.com 2025-03-12 18:12:00 Czytaj oryginał (ang.)
Tarsus Pharma: Strong Execution In Xdemvy Commercialization Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects. seekingalpha.com 2025-03-11 14:36:17 Czytaj oryginał (ang.)
Tarsus to Participate in Upcoming Investor Conference IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET. globenewswire.com 2025-03-06 19:00:00 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded. seekingalpha.com 2025-02-25 20:01:18 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago. zacks.com 2025-02-25 11:40:30 Czytaj oryginał (ang.)
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update. globenewswire.com 2025-02-20 19:00:00 Czytaj oryginał (ang.)
Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences: globenewswire.com 2025-01-30 19:00:00 Czytaj oryginał (ang.)
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2025-01-14 12:36:16 Czytaj oryginał (ang.)
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 globenewswire.com 2025-01-13 10:30:00 Czytaj oryginał (ang.)
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. zacks.com 2024-12-24 14:51:19 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. seekingalpha.com 2024-12-15 16:00:00 Czytaj oryginał (ang.)
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-12-04 12:56:14 Czytaj oryginał (ang.)
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-11-18 13:00:36 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - CFO and CSO Sesha Neervannan - COO Elizabeth Yeu - Chief Medical Officer Conference Call Participants Eddie Hickman - Guggenheim Securities Lachlan Hanbury-Brown - William Blair Andrea Newkirk - Goldman Sachs Oren Livnat - HC Wainwright Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Corey Jubinville - Life Sci Capital Francois Brisebois - Oppenheimer Operator Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded at this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. seekingalpha.com 2024-11-14 00:23:06 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. zacks.com 2024-11-13 20:31:12 Czytaj oryginał (ang.)
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes globenewswire.com 2024-11-13 10:30:00 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-11-07 13:00:30 Czytaj oryginał (ang.)
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. globenewswire.com 2024-11-06 18:30:00 Czytaj oryginał (ang.)
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization globenewswire.com 2024-11-05 10:30:00 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2024-10-30 09:41:10 Czytaj oryginał (ang.)
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids globenewswire.com 2024-10-17 12:30:00 Czytaj oryginał (ang.)
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 taking place on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET. globenewswire.com 2024-09-25 21:00:00 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 results and ongoing FDA discussions. Strong financials with $323M in cash reserves, a healthy current ratio, and a projected positive cash flow by Q3 2024 support robust growth. seekingalpha.com 2024-09-20 19:17:34 Czytaj oryginał (ang.)
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in Boston, MA, on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET. globenewswire.com 2024-08-28 21:00:00 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with a $1 billion market opportunity in the initial addressable segment alone. TARS has promising data in trials for various conditions, including Lyme disease and Meibomian gland disease, with potential preventive and therapeutic benefits. seekingalpha.com 2024-08-20 20:56:17 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and CSO Sesha Neervannan - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Pavan Patel - BofA Dennis Kennedy - LifeSci Capital Talani Usman - Goldman Sachs Frank Brisebois - Oppenheimer Michaela Diverio - Barclays Eddie Hickman - Guggenheim Securities Operator Good afternoon. And welcome to the Tarsus' Second Quarter 2024 Financial Results Conference Call. seekingalpha.com 2024-08-10 17:50:04 Czytaj oryginał (ang.)
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago. zacks.com 2024-08-08 23:07:04 Czytaj oryginał (ang.)
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update. globenewswire.com 2024-07-29 20:30:00 Czytaj oryginał (ang.)
Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences: globenewswire.com 2024-05-29 21:00:00 Czytaj oryginał (ang.)